<DOC>
	<DOCNO>NCT01872416</DOCNO>
	<brief_summary>At present , standard second-line treatment refractory relapse SCLC , topotecan , gemcitabine , paclitaxel , irinotecan drug cyclophosphamide second-line treatment small cell lung cancer currently explore , Anthracycline antibiotic cell cycle non-specific anticancer drug could inhibit synthesis DNA , DNA dependent RNA , wide antitumor spectrum , widely use malignant hematologic disease lung cancer solid tumor . Jacot W , et al evaluate epirubicin combine ifosfamide ( EI ) treatment refractory recurrent SCLC 70 case , objective response rate ( ORR ) reach 21.4 % , include 1 case complete remission , 10 % patient obtain stable disease ( SD ) , patient median survival 3.9 month , ( 71 % ) patient neutropenia , platelet count anemia also common , show EI treatment refractory relapse SCLC effectively control , toxicity . In view epirubicin combine ifosfamide ( EI ) scheme effective safety treatment refractory relapse SCLC , investigator use liposomal doxorubicin plus ifosfamide second-line treatment refractory relapse small cell lung cancer , may obtain good tumor remission rate , improve prognosis patient .</brief_summary>
	<brief_title>A Clinical Study Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment Small Cell Lung Cancer</brief_title>
	<detailed_description>investigator evaluate overall response rate ( complete partial response ) first-line treatment failure relapse first-line therapy SCLC treat Pegylated liposomal doxorubicin ifosfamide We evaluate progression-free survival ( PFS ) overall survival ( OS ) receive first-line treatment failure relapse first-line therapy SCLC treat Pegylated liposomal doxorubicin ifosfamide</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>1 . Male female patient &gt; =18 year age 2. histological diagnosis small cell lung cancer ; 3 . Patients firstline treatment failure relapse firstline therapy ; 4. enough tumor tissue specimens molecular marker analysis ; 5 . Measurable disease RECIST criteria 6 . ECOG performance status &lt; =2 . 7 . Life expectancy least 3 month . 8 . Laboratory value follow : : ANC ≥ 1.5 × 109/L ; platelet count ≥ 100 × 109/L ; HB ≥ 90g/L ; serum bilirubin ≤ 1.5 upper limit normal ( N ) ; ALT/AST≤ 2N ( patient liver metastasis : ALT/AST≤ 5N ) creatinine≤1.25 N ; clearance rate creatinine ≥ 60mLl/min ; proteinuria &lt; 2+ , detect 24 hour urine protein , protein content ≤1g 9 . Patient must accessible treatment followup 10 . All patient must able understand nature study give write informed consent prior study entry 1. mixed small cell lung cancer ; 2. patient previous diagnosis malignant tumor ; 3 . HIV infection ; 4 . A history cardiac disease define malignant hypertension , unstable angina , congestive heart failure &gt; grade 2 per New York Heart Association ( NYHA ) criterion , myocardial infarction within previous 6 month , symptomatic cardiac arrhythmia . 5. patient motor sensory neuron lesions/symptoms NCI CTC AE &gt; 1 ; 6. patient serious active infection ; 7. patient allergic ifosfamide liposomal doxorubicin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Refractory relapse small cell lung cancer</keyword>
	<keyword>Liposomal Doxorubicin</keyword>
	<keyword>ifosfamide</keyword>
</DOC>